% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zecha:274352,
      author       = {J. Zecha$^*$ and F. P. Bayer and S. Wiechmann$^*$ and J.
                      Woortman and N. Berner$^*$ and J. Müller and A. Schneider
                      and K. Kramer and M. Abril-Gil and T. Hopf and L. Reichart
                      and L. Chen and F. M. Hansen and S. Lechner and P. Samaras
                      and S. Eckert$^*$ and L. Lautenbacher and M. Reinecke and F.
                      Hamood and P. Prokofeva and L. Vornholz and C.
                      Falcomatà$^*$ and M. Dorsch$^*$ and A. Schröder and A.
                      Venhuizen and S. Wilhelm and G. Médard and G. Stoehr and J.
                      Ruland$^*$ and B. Grüner$^*$ and D. K. M. Saur$^*$ and M.
                      Buchner and B. Ruprecht and H. Hahne and M. The and M.
                      Wilhelm and B. Kuster$^*$},
      title        = {{D}ecrypting drug actions and protein modifications by
                      dose- and time-resolved proteomics.},
      journal      = {Science},
      volume       = {380},
      number       = {6640},
      issn         = {0036-8075},
      address      = {Cambridge, Mass.},
      publisher    = {Moses King},
      reportid     = {DKFZ-2023-00554},
      pages        = {93-101},
      year         = {2023},
      note         = {2023 Apr 7;380(6640):93-101},
      abstract     = {Although most cancer drugs modulate the activities of
                      cellular pathways by changing post-translational
                      modifications (PTMs), surprisingly little is known regarding
                      the extent and the time- and dose-response characteristics
                      of drug-regulated PTMs. Here, we introduce a proteomic assay
                      termed decryptM that quantifies drug-PTM modulation for
                      thousands of PTMs in cells to shed light on target
                      engagement and drug mechanism of action (MoA). Examples
                      range from detecting DNA damage by chemotherapeutics, to
                      identifying drug-specific PTM signatures of kinase
                      inhibitors, to demonstrating that rituximab kills
                      CD20-positive B-cells by over-activating B cell receptor
                      signaling. DecryptM profiling of 31 cancer drugs in 13 cell
                      lines demonstrates the broad applicability of the approach.
                      The resulting 1.8 million dose-response curves are provided
                      as an interactive molecular resource in ProteomicsDB.},
      cin          = {MU01 / ED01},
      ddc          = {500},
      cid          = {I:(DE-He78)MU01-20160331 / I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36926954},
      doi          = {10.1126/science.ade3925},
      url          = {https://inrepo02.dkfz.de/record/274352},
}